FDA announce a new approval of TUKYSA® (tucatinib, Seagen Inc.) tablets, for oral use in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Access the Full Prescribing Information for TUKYSA. Read More.